James Payne, MD
Radiation Oncology · Albertville, ALNPI 1952342982
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Novartis at 25.5% of the total. Reporting peaked in 2019 at $577 and has fallen 51.1% since, to $282 in 2025.
Across 105 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$468
- Johnson & Johnson$222
- Merck$145
- Astellas Pharma US Inc$120
- E.r. Squibb & Sons, L.L.C.$112
- AbbVie$88
- plus $682 from 22 others
What the payments were for
- Food & beverage$1,837100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 24 | $468 |
| Johnson & Johnson(2 entities) | 13 | $222 |
| Merck | 8 | $145 |
| Astellas Pharma US Inc | 7 | $120 |
| E.r. Squibb & Sons, L.L.C. | 9 | $112 |
| AbbVie | 4 | $88 |
| Bayer | 6 | $87 |
| AstraZeneca | 3 | $52 |
| Stemline Therapeutics Inc. | 2 | $48 |
| Novocure Inc. | 3 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Amgen | 3 | $39 |
| Sumitomo Pharma America, Inc. | 2 | $39 |
| Pfizer | 2 | $37 |
| Daiichi Sankyo Inc. | 2 | $33 |
| Calyxo, Inc. | 1 | $31 |
| Pharmaessentia USA Corporation | 1 | $25 |
| Myovant Sciences Inc. | 2 | $25 |
| Progenics Pharmaceuticals, Inc. | 1 | $22 |
| Sanofi | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Dova Pharmaceuticals | 1 | $19 |
| Tolmar Pharmaceuticals, Inc. | 1 | $17 |
| Visionrt, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $13 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $12 |
| EMD Serono, Inc. | 1 | $11 |
How this compares
$1,837 in reported general payments places this provider in the 60th percentile of 87 radiation oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pilocarpine Hcl | 27 | $1,407 |
| Pentoxifylline | 18 | $1,146 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 27 | $774 |
| SsdSilver Sulfadiazine | 11 | $401 |
| Tamsulosin Hcl | 38 | $372 |
| Silver Sulfadiazine | 12 | $366 |
| Solifenacin Succinate | 20 | $354 |
| Levothyroxine Sodium | 26 | $205 |
| Lidocaine Hcl ViscousLidocaine Hcl | 11 | $170 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Albertville
- Alexander WhitleyMontgomery$441K
- Drexell BoggsBirmingham$35K
- Christopher JahrausAlabaster$28K
- Christopher WilleyBirmingham$13K
- Adam KoleBirmingham$11K
- William HixsonFairhope$10K
- John GleasonHuntsville$9K
- Andrew McDonaldBirmingham$8K
- Hoyt ChildsHuntsville$7K
- James TuckerTuscaloosa$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.